Wolverine Trading
AVDL

Wolverine Trading’s Avadel Pharmaceuticals AVDL Stock Holding History

Wolverine Trading’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$378K Buy
+24,700
New +$321K ﹤0.01% 4041
2025
Q2 		– Sell
-13,800
Closed -$111K – 4717
2025
Q1 		$111K Sell
13,800
-7,400
-35% -$62K ﹤0.01% 4195
2024
Q4 		$223K Sell
21,200
-6,200
-23% -$75.3K ﹤0.01% 4387
2024
Q3 		$349K Buy
27,400
+11,800
+76% +$180K ﹤0.01% 3435
2024
Q2 		$219K Buy
+15,600
New +$254K ﹤0.01% 3752
2024
Q1 		– Sell
-39,400
Closed -$556K – 4473
2023
Q4 		$556K Buy
39,400
+6,000
+18% +$70.5K ﹤0.01% 2850
2023
Q3 		$344K Buy
33,400
+15,800
+90% +$212K ﹤0.01% 3156
2023
Q2 		$261K Buy
+17,600
New +$229K ﹤0.01% 3245
2022
Q3 		– Sell
-13,600
Closed -$32K – 4571
2022
Q2 		$32K Buy
13,600
+1,200
+10% +$4.93K ﹤0.01% 4164
2022
Q1 		$87K Buy
+12,400
New +$85.2K ﹤0.01% 4876
2021
Q3 		– Sell
-10,300
Closed -$72K – 6232
2021
Q2 		$72K Sell
10,300
-4,400
-30% -$34.9K ﹤0.01% 5520
2021
Q1 		$130K Sell
14,700
-300
-2% -$2.43K ﹤0.01% 5312
2020
Q4 		$100K Sell
15,000
-5,100
-25% -$31.9K ﹤0.01% 4462
2020
Q3 		$103K Sell
20,100
-24,600
-55% -$179K ﹤0.01% 4123
2020
Q2 		$355K Sell
44,700
-33,900
-43% -$299K ﹤0.01% 3117
2020
Q1 		$685K Buy
+78,600
New +$604K ﹤0.01% 2310
2019
Q4 		– Sell
-45,100
Closed -$192K – 4628
2019
Q3 		$192K Buy
+45,100
New +$113K ﹤0.01% 3616
2018
Q3 		– Sell
-16,200
Closed -$118K – 4901
2018
Q2 		$118K Hold
16,200
– – ﹤0.01% 4657
2018
Q1 		$118K Buy
+16,200
New +$143K ﹤0.01% 4657

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Wolverine Trading's AVDL Position: Q1 2024 in Review

Wolverine Trading sold out of Avadel Pharmaceuticals (AVDL) in Q1 2024, closing a stake of 20,776 shares — an estimated $293K sold.

Wolverine Trading first reported a position in AVDL in Q4 2017 and held it in 9 quarters. The position peaked at $293K in Q4 2023. 127 funds tracked by Wall St. Rank hold AVDL as of Q1 2024.

  • Wolverine Trading reported no remaining Avadel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Wolverine Trading sold 20,776 Avadel Pharmaceuticals shares in Q1 2024, an estimated $293K.
  • Wolverine Trading first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 9 quarters.
  • Wolverine Trading's Avadel Pharmaceuticals position peaked at $293K in Q4 2023.
  • 127 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2024.

Based on Wolverine Trading's 13F filing for Q1 2024, filed 15 May 2024.